Update and Clinical Implications of the SPRINT Trial

Topic: date: 07/01/2016 Featured Expert: Suzanne Oparil, MD

The SPRINT trial created both excitement and controversy in the medical community when it was realized aggressive blood pressure lowering to a target of 120 mmHg resulted in...


The SPRINT trial created both excitement and controversy in the medical community when it was realized aggressive blood pressure lowering to a target of 120 mmHg resulted in significant reductions in cardiovascular events and all-cause mortality. These reductions were seen in all of SPRINT’s subgroups including those older than age 75, persons with previous CAD, and those with chronic kidney disease. In her Keynote presentation, “Update and Clinical Implications of the SPRINT Trial,” Suzanne Oparil, MD, one of the principal investigators of the trial, will discuss the benefits seen in SPRINT as well as its caveats while touching on some of the ongoing substudies, including a cost-effectiveness analysis and a mind outcomes study examining the question of whether aggressive blood pressure lowering preserves cognitive function and brain structure.

BACK